m6A-centered Drug Response Information
General Information of the Drug (ID: M6ADRUG0067)
| Name |
Arsenite
|
||||
|---|---|---|---|---|---|
| Synonyms |
Sodium metaarsenite; Sodium dioxoarsenate; sodium;oxoarsinite; Arsenite, sodium; UNII-48OVY2OC72; NaAsO2; Sodium (meta)arsenite; 48OVY2OC72; CHEBI:29678; Arsenenous acid, sodium salt (1:1); Prodalumnol; Sodanit; Penite; Kill-All; Prodalumnol double; Rat Death Liquid; Chem Pels C; sodium meta-arsenite; Chem-Sen 56; Caswell No. 744; MFCD00003472; Atlas A; Arsenite de sodium; Arsenenous acid, sodium salt; Arsenite de sodium [French]; Arsenious acid, monosodium salt; CCRIS 5554; HSDB 693; EINECS 232-070-5; EPA Pesticide Chemical Code 013603; Sodium arsenenite; AsO2.Na; (NaAsO2)n; CHEMBL1909078; DTXSID5020104; Sodium (meta)arsenite, >=90%; 5497AF; AKOS025295751; Na(+)n-(-As(O(-))O-)-n; Sodium (meta)arsenite, p.a., 98.0%; catena-poly[(oxidoarsenate-mu-oxido)]sodium; Sodium arsenite, 0.1N Standardized Solution; Sodium arsenite, 0.5M standardized solution; Q419586
Click to Show/Hide
|
||||
| Status | Phase 2 | [1] | |||
| Structure |
 |
||||
|
3D MOL
|
|||||
| Formula |
AsNaO2
|
||||
| InChI |
InChI=1S/AsHO2.Na/c2-1-3;/h(H,2,3);/q;+1/p-1
|
||||
| InChIKey |
PTLRDCMBXHILCL-UHFFFAOYSA-M
|
||||
| PubChem CID | |||||
Full List of m6A Targets Related to This Drug
Cellular tumor antigen p53 (TP53/p53)
| In total 2 item(s) under this target gene | ||||
| Experiment 1 Reporting the m6A-centered Drug Response by This Target Gene | [2] | |||
| Response Summary | METTL3 significantly decreased m6A level, restoring Cellular tumor antigen p53 (TP53/p53) activation and inhibiting cellular transformation phenotypes in the arsenite-transformed cells. m6A downregulated the expression of the positive p53 regulator, PRDM2, through the YTHDF2-promoted decay of PRDM2 mRNAs. m6A upregulated the expression of the negative p53 regulator, YY1 and MDM2 through YTHDF1-stimulated translation of YY1 and MDM2 mRNA. This study further sheds light on the mechanisms of arsenic carcinogenesis via RNA epigenetics. | |||
| Responsed Disease | Solid tumour/cancer | ICD-11: 2A00-2F9Z | ||
| Target Regulator | YTH domain-containing family protein 1 (YTHDF1) | READER | ||
| Target Regulation | Down regulation | |||
| Pathway Response | p53 signaling pathway | hsa04115 | ||
| In-vitro Model | HaCaT | Normal | Homo sapiens | CVCL_0038 |
| Experiment 2 Reporting the m6A-centered Drug Response by This Target Gene | [2] | |||
| Response Summary | METTL3 significantly decreased m6A level, restoring Cellular tumor antigen p53 (TP53/p53) activation and inhibiting cellular transformation phenotypes in the arsenite-transformed cells. m6A downregulated the expression of the positive p53 regulator, PRDM2, through the YTHDF2-promoted decay of PRDM2 mRNAs. m6A upregulated the expression of the negative p53 regulator, YY1 and MDM2 through YTHDF1-stimulated translation of YY1 and MDM2 mRNA. This study further sheds light on the mechanisms of arsenic carcinogenesis via RNA epigenetics. | |||
| Responsed Disease | Solid tumour/cancer | ICD-11: 2A00-2F9Z | ||
| Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
| Target Regulation | Up regulation | |||
| Pathway Response | p53 signaling pathway | hsa04115 | ||
| In-vitro Model | HaCaT | Normal | Homo sapiens | CVCL_0038 |
PR domain zinc finger protein 2 (PRDM2)
| In total 2 item(s) under this target gene | ||||
| Experiment 1 Reporting the m6A-centered Drug Response by This Target Gene | [2] | |||
| Response Summary | METTL3 significantly decreased m6A level, restoring p53 activation and inhibiting cellular transformation phenotypes in the arsenite-transformed cells. m6A downregulated the expression of the positive p53 regulator, PR domain zinc finger protein 2 (PRDM2), through the YTHDF2-promoted decay of PRDM2 mRNAs. m6A upregulated the expression of the negative p53 regulator, YY1 and MDM2 through YTHDF1-stimulated translation of YY1 and MDM2 mRNA. This study further sheds light on the mechanisms of arsenic carcinogenesis via RNA epigenetics. | |||
| Responsed Disease | Solid tumour/cancer | ICD-11: 2A00-2F9Z | ||
| Target Regulator | YTH domain-containing family protein 1 (YTHDF1) | READER | ||
| Target Regulation | Down regulation | |||
| Pathway Response | p53 signaling pathway | hsa04115 | ||
| In-vitro Model | HaCaT | Normal | Homo sapiens | CVCL_0038 |
| Experiment 2 Reporting the m6A-centered Drug Response by This Target Gene | [2] | |||
| Response Summary | METTL3 significantly decreased m6A level, restoring p53 activation and inhibiting cellular transformation phenotypes in the arsenite-transformed cells. m6A downregulated the expression of the positive p53 regulator, PR domain zinc finger protein 2 (PRDM2), through the YTHDF2-promoted decay of PRDM2 mRNAs. m6A upregulated the expression of the negative p53 regulator, YY1 and MDM2 through YTHDF1-stimulated translation of YY1 and MDM2 mRNA. This study further sheds light on the mechanisms of arsenic carcinogenesis via RNA epigenetics. | |||
| Responsed Disease | Solid tumour/cancer | ICD-11: 2A00-2F9Z | ||
| Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
| Target Regulation | Up regulation | |||
| Pathway Response | p53 signaling pathway | hsa04115 | ||
| In-vitro Model | HaCaT | Normal | Homo sapiens | CVCL_0038 |
References